Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
NCT05229341
Summary
This clinical trial evaluates deoxyribonucleic acid (DNA) methylation signatures in diagnosing and managing thyroid nodules. The purpose of this research is to develop a new test for thyroid cancer. This test will use needle biopsies (small collections of tissue with a needle) from the thyroid to determine whether the participant has a malignant (cancer) or benign (not showing cancer) thyroid tumor. The information learned from this trial may help develop a more accurate test so that patients do not have unnecessary surgeries for nodules that are thought to be suspicious but are actually benign.
Eligibility
Inclusion Criteria: * Patients without impaired decision-making capacity and who are undergoing needle biopsies for thyroid nodule diagnosis * Over the age of 18 * Any gender, race and ethnicity * Patients must provide informed consent prior to use of their tissues and clinical data Exclusion Criteria: * Children are excluded from the study, since the biology of children thyroid nodules is different from adults
Conditions2
Locations1 site
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT05229341